Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab ; day:2 ; month:5 ; year:2017 ; pages:1-3
Investigational new drugs ; (2.5.2017), 1-3
- Urheber
-
Mamesaya, Nobuaki
- Beteiligte Personen und Organisationen
-
Kenmotsu, Hirotsugu
Takahashi, Toshiaki
SpringerLink (Online service)
- DOI
-
10.1007/s10637-017-0471-y
- URN
-
urn:nbn:de:1111-201705134952
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mamesaya, Nobuaki
- Kenmotsu, Hirotsugu
- Takahashi, Toshiaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis